With the present COVID‐19 vaccination drive across the world, adverse skin reactions post COVID‐19 vaccine is expected. Majority of these reactions seen were transient or local injection site reactions. However, as the larger population is being vaccinated, certain uncommon dermatological presentations including leukocytoclastic vasculitis, pityriasis rosea, and exacerbation of pre‐existing autoimmune diseases are now being reported. Among all the COVID‐19 vaccines, most of these reactions are seen with messenger ribonucleic acid‐based Pfizer/BioNTech (BNT162b2) and Moderna (mRNA‐1273) vaccine. We report two cases of leukocytoclastic vasculitis following ChAdOx1 nCoV‐19 corona virus vaccine (recombinant) that bring out potential new dermatological manifestations of recombinant corona virus vaccine being administered across the European, South American, and Asian countries. It is important for all health care workers and patients to be aware of the corona virus vaccine associated adverse cutaneous reactions.

Leprosy presenting with vascular involvement is very rare or is probably under-reported. Arteriographic and histopathological analysis has shown vascular involvement in few individuals with leprosy previously. It has also been found that vascular abnormality is central to the pathogenesis of trophic ulcer and nerve damage itself. A 37-year-old male presented to our center with pain, bluish discoloration and recurrent ulceration of digits of hands and feet of twelve months duration. Investigations revealed diminished caliber of the brachial artery with no other underlying abnormality. Dermatological review revealed features of primary neuritic leprosy confirmed by nerve biopsy and polymerase chain reaction (PCR) for Mycobacterium leprae positivity. This case highlights the fact that vascular involvement could rarely be a primary event in leprosy and cause Buerger's disease-like manifestations.

investigation, the median age of HGPS diagnosis was 3 month, much earlier than 2.9 years reported in the United States and 2.6 years in Europe. 2 We found the facial dysmorphism, sclerotic skin, and a 'protuberant bikini sign' are the most valuable clue for early clinical diagnosis, and could help to facilitate first sight recognition. The significant 'protuberant bikini sign' was first reported in our article and might also help to make differential diagnosis with other reasons of sclerotic skin such as sclerema neonatorum.Some of the manifestations were not commonly observed as literature described, such as loss of scalp hair, dystrophic nails, cardiovascular and endocrine complications. 4,5 These could be explained as the clinical manifestation gradually progresses depending on ages, and the evaluation ages of our patients were too young to develop these complications.Skin histopathology is not helpful in diagnosis. LMNA sequencing is essential when HGPS is suspected. The c.1824C>T mutation is most frequent that refers to classic type HGPS, 4 as in 66.7% of our cases. The atypical c.1968+1G>T mutation in case 3 results in the most severe manifestation and the only death among these patients. It is also the second report about this mutation that causes severe progeroid syndromes. 6 In case 6, the atypical heterozygous IVS8, À4 C>A was a novel mutation in the Human Gene Mutation Database (HGMD).In conclusion, HGPS have characteristic clinical features that facilitate first sight recognition, and LMNA gene mutation is necessary for early diagnosis. A detailed multi-system examination with close monitoring is important to extend the lifespan.

Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell neoplasms characterized by bone marrow failure leading to ineffective hematopoiesis, dyspoiesis, and cytopenias with a risk of progression to acute leukemia. Immunological syndromes have been reported to occur along with MDS in literature. However, cold autoimmune hemolytic anemia (AIHA) has rarely been reported in association with MDS. Herein, we report a case of an elderly male who presented with fever and cytopenias. He was being treated as a case of megaloblastic anemia in the past with no response to therapy. At present admission, the peripheral blood smear examination revealed red cell agglutination, thrombocytopenia with 4% blasts. Cold agglutinin disease was confirmed by a thermal agglutination test and bone marrow evaluation showed adequate megakaryocytes with 10% blasts; consistent with the diagnosis of MDS with excess blasts (MDS-EB2). Cytogenetic studies revealed multiple abnormalities. This report is being discussed in view of its rarity of presentation of cold AIHA with MDS.

No abstract